Emyria Ltd (ASX:EMD) and the Pax Centre are aiming to make history as the first, integrated service in Australia to offer psychedelic-assisted therapy in a community practice.
This follows Emyria’s acquisition of the Pax Centre in Perth, a multidisciplinary psychological trauma care centre.
Emyria can now advance multiple therapy development programs, across ultra-pure cannabinoids, MDMA-analogues and psychedelic-assisted therapies - each with large patient populations and market potential.
Emyria’s clinical service evolution.
Emyria stands at the forefront of the psychedelic-assisted therapy revolution and is uniquely positioned with a base in Australia - where groundbreaking regulatory changes in mental health treatment are occurring.
The company’s extensive experience with unregistered treatments, mastery of data-driven patient care and now the acquisition of the Pax Centre have all consolidated its industry leadership.
Emyria's strategic acquisition of the Pax Centre is a significant step toward establishing a global Centre of Excellence for the development and delivery of innovative and sustainable therapies, including psychedelic-assisted therapy.
By integrating operations with Emyria's GP-led service, Emerald Clinics, the company aims to generate operational synergies and opportunities for real-world data collection, fortifying its leadership position in mental health care delivery and improving patient outcomes.
This acquisition also aligns with Emyria's plans to advance patient recruitment and foster payer engagement for the ethics-approved pivotal trial for MDMA-assisted Post-Traumatic Stress Disorder therapy (EMDMA-001).
Emyria has already received more than 100 expressions of interest for this trial and plans to expedite the development of psilocybin-assisted therapy protocols for treatment-resistant depression.
Emyria’s managing director Dr Michael Winlo recently said: “This acquisition is a transformation for Emyria. By integrating Pax's multidisciplinary team into our existing clinical operations, we're strengthening our clinical service foundations and building a unique model for the delivery of emerging mental health treatments, such as psychedelic-assisted therapies.
"The acquisition also improves our ability to collect crucial clinical data that can help engage payers as well as drive further care model improvements and novel drug development.”
Emyria’s major achievements and near-term catalysts.
Read more on Proactive Investors AU
